Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) EPS (Basic) (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed EPS (Basic) for 6 consecutive years, with -$0.17 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 41.38% to -$0.17 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.0, a 12.28% increase, with the full-year FY2025 number at -$1.0, up 12.28% from a year prior.
  • EPS (Basic) was -$0.17 for Q4 2025 at TScan Therapeutics, up from -$0.28 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $9.7 in Q3 2021 to a low of -$7.76 in Q2 2021.
  • A 5-year average of -$0.52 and a median of -$0.29 in 2024 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): surged 235.47% in 2021, then tumbled 302.63% in 2022.
  • TScan Therapeutics' EPS (Basic) stood at $0.38 in 2021, then crashed by 302.63% to -$0.77 in 2022, then skyrocketed by 141.56% to $0.32 in 2023, then crashed by 190.62% to -$0.29 in 2024, then soared by 41.38% to -$0.17 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's EPS (Basic) are -$0.17 (Q4 2025), -$0.28 (Q3 2025), and -$0.29 (Q2 2025).